- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02266940
Relative Bioavailability DS-1971a Suspension and Tablets and Food Effect on DS-1971a Tablets
20 december 2018 uppdaterad av: Daiichi Sankyo, Inc.
A Phase 1, Open Label, Randomised, Single Dose, Three Way Crossover Study to Explore the Relative Bioavailability of DS 1971a Given as a 200 mg Tablet Formulation and a 200 mg Oral Suspension, and to Explore the Effects of Administration With a High Fat Meal on the Relative Bioavailability of the Tablet Formulation
This is an open label, randomised, 3 treatment, 3 period crossover study.
This study is designed to assess the relative bioavailability of DS 1971a from a tablet formulation and a reconstituted oral suspension and the effect of a high fat meal on the relative bioavailability of DS 1971a from the tablet formulation.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Faktisk)
18
Fas
- Fas 1
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
-
London, Storbritannien, NW10 7EW
- Hammersmith Medicines Research Ltd
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år till 65 år (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Ja
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Male or female subjects aged 18 to 65 years, inclusive
- Subjects must be in good general health as determined by medical history, physical examination and screening investigations, and be taking no regular medication
- A body mass index (BMI) in the range 18 to 30 kg/m^2, inclusive, and weighing between 50 and 100 kg. BMI is calculated as weight [kg]/(height [m])^2
- Female subjects must be of nonchildbearing potential as follows:
Must be postmenopausal (the last menstrual period was at least 12 months before Screening, and a follicle stimulating hormone [FSH] test at Screening confirms postmenopausal status); or Must be surgically sterile having undergone hysterectomy, bilateral oophorectomy, bilateral salpingectomy and/or bilateral tubal ligation
- Willing and able to consume a standard Food and Drug Administration (FDA) high fat meal
- Willing to comply with all study restrictions, including the use of contraception, concomitant medication, and dietary and lifestyle restrictions
- Sufficient intelligence to understand the nature of the study and any hazards of participating in it. Ability to communicate satisfactorily with the Investigator and to participate in, and comply with the requirements of, the entire study
- Have given written consent to participate after reading the information and consent form, and after having the opportunity to discuss the study with the Investigator or his/her delegate
- Have given written consent to have his/her data entered into The Over-volunteering Prevention System (TOPS)
Exclusion Criteria:
- Clinically relevant abnormal history, physical findings, ECG findings, or laboratory values that could interfere with the objectives of the study or the safety of the subject
- Presence of or history of acute or chronic illness, including (but not limited to) liver or kidney disease, hypertension, seizures, or any known impairment of endocrine, or other specific body-organ dysfunction
- Presence or history of severe adverse reaction to any medicine
- Presence or history of malignant disease
- Acute or chronic infectious disease, including human immunodeficiency virus (HIV), hepatitis B virus (HBV) or C virus (HCV) infection
- Surgery (eg, stomach bypass) or medical condition that might affect absorption of medicines
- Significant illness within 4 weeks before the dose of study medication
- Participation in another clinical study of a new chemical entity or a prescription medicine within the previous 3 months, or unwilling to abstain from participating in other clinical studies during the study and for 3 months after receipt of their final dose of study medication
- Participation in another clinical study with DS-1971a
- Blood pressure (BP) and heart rate in semi supine position at the screening examination outside the ranges 90-140 mmHg systolic, 40-90 mmHg diastolic; heart rate 40-100 beats/min. Subjects with Stage 1 hypertension (systolic 140 160 mmHg; diastolic 90 100 mmHg) may be enrolled provided they do not have evidence of end organ damage, diabetes or a 10 year cardiovascular risk >20%
- Estimated glomerular filtration rate (eGFR) <80 mL/min/1.73m^2 or an absolute creatinine value above the upper limit of normal (ULN). eGFR will be estimated at Screening using the modification of diet in renal disease (MDRD) equation
- Abnormal ECG waveform morphology at Screening that would preclude accurate measurement of the QT interval duration
- Corrected QT interval (Fridericia's formula) (QTcF) interval duration >430 msec for men or >450 msec for women, obtained as an average from the measurements on duplicate screening ECGs
- Use of any prescription medicine or over-the-counter (OTC) medications, herbal remedies (such as St John's Wort), or food known to be strong inhibitors or strong inducers of cytochrome (CYP) enzymes (also known as CYP450 enzymes) during the 30 days before the dose of study medication; use of any other prescription or OTC medicine, including dietary supplements or herbal remedies, during the 7 days before the first dose of study medication
- Consumption of certain foods or beverages before the dose and throughout the study period
- Loss of more than 400 mL blood during the 3 months before the study, eg, as a blood donor
- Abuse of drugs or alcohol during the 2 years before the first dose of study medication, or intake of more than 21 units of alcohol weekly (for men) or 14 units of alcohol weekly (for women)
- Use of tobacco products or nicotine containing products during the 3 months before the dose of trial medication
- Likely possibility that the volunteer will not cooperate with the requirements of the protocol
- Objection by General Practitioner (GP) to volunteer entering the study
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Grundläggande vetenskap
- Tilldelning: Randomiserad
- Interventionsmodell: Crossover tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: 200mg DS-1971a oral suspension fasted
200 mg DS 1971a given as oral suspension in fasted condition
|
DS 1971a will be supplied as a powder or crystals and prepared at the study site for administration as an oral suspension with a taste masking agent.
|
Experimentell: 200 mg DS-1971a tablet fasted
single 200 mg DS 1971a oral tablet in fasted condition
|
A 200 mg DS 1971a tablet for oral administration
|
Experimentell: 200 mg DS-1971a tablet fed
single 200 mg DS 1971a oral tablet given in fed condition
|
A 200 mg DS 1971a tablet for oral administration
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Pharmacokinetics profile of DS-1971a
Tidsram: 3 days from dose administration
|
Plasma concentration time data will be analysed using non compartmental methods.
The following PK parameters will be estimated: Cmax, Tmax and AUClast.
If data permit, AUC0-inf, CL/F, Vd/F and T½ will be estimated.
|
3 days from dose administration
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
number and severity of adverse events as a measure of safety and tolerability
Tidsram: administration of first dose to 10 weeks
|
number and severity of adverse events as a measure of safety and tolerability
|
administration of first dose to 10 weeks
|
changes in clinical laboratory profile
Tidsram: administration of first dose to 10 weeks
|
haematology, biochemistry, and urinalysis
|
administration of first dose to 10 weeks
|
changes in physical exam profile
Tidsram: administration of first dose to 10 weeks
|
Physical examination profile includes; Height and weight, heart rate, blood pressure (BP), oral temperature and respiration rate, 12 lead electrocardiogram (ECG)
|
administration of first dose to 10 weeks
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 november 2014
Primärt slutförande (Faktisk)
1 januari 2015
Avslutad studie (Faktisk)
1 januari 2015
Studieregistreringsdatum
Först inskickad
9 oktober 2014
Först inskickad som uppfyllde QC-kriterierna
16 oktober 2014
Första postat (Uppskatta)
17 oktober 2014
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
24 december 2018
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
20 december 2018
Senast verifierad
1 januari 2015
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- DS1971-A-E104
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
JA
IPD-planbeskrivning
De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/.
In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants.
Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
Tidsram för IPD-delning
Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
Kriterier för IPD Sharing Access
Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research.
This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
- ICF
- ANALYTIC_CODE
- CSR
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Friska
-
University of MiamiJames and Esther King Biomedical Research ProgramAvslutadHealthy Lifetime Icke-rökareFörenta staterna
-
University of LeicesterNational Institute for Health Research, United KingdomAvslutadPatienter med hjärtsvikt och konserverad ejektionsfraktion - HFpEF | Patienter med hjärtsvikt med reducerad ejektionsfraktion - HFrEF | Healthy Controls Group - ålders- och könsmatchad
-
University Hospital, GrenobleUniversity Hospital, Clermont-Ferrand; Grenoble Institut des NeurosciencesAvslutadParkinsons sjukdom | Healthy Controls Group - ålders- och könsmatchadFrankrike
Kliniska prövningar på DS-1971a suspension
-
Daiichi Sankyo, Inc.Avslutad
-
Daiichi Sankyo, Inc.Avslutad
-
Medtronic BRCOkändHjärtsviktStorbritannien
-
Daiichi Sankyo Co., Ltd.RekryteringFast tumör | Metastatisk fast tumör | Avancerad cancerJapan, Förenta staterna, Kanada
-
Daiichi Sankyo Co., Ltd.AvslutadAvancerade solida maligna tumörerJapan
-
Institut National de la Santé Et de la Recherche...Ultragenyx Pharmaceutical IncAvslutadGlut1-bristsyndromFrankrike
-
Daiichi Sankyo, Inc.AvslutadNedsatt leverfunktionFörenta staterna
-
Daiichi Sankyo Co., Ltd.Avslutad
-
Daiichi Sankyo Co., Ltd.Avslutad